CC
JAZZ icon

Caxton Corporation’s Jazz Pharmaceuticals JAZZ Stock Holding History

Caxton Corporation’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,997
Closed -$306K – 21
2017
Q3 		$306K Buy
1,997
+7
+0.4% +$1.06K 0.31% 14
2017
Q2 		$309K Sell
1,990
-2
-0.1% -$306 0.48% 9
2017
Q1 		$289K Buy
+1,992
New +$259K 0.82% 9

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
SIG
Senator Investment Group New York $2.74B AUM 55.95% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Caxton Corporation's JAZZ Position: Q4 2017 in Review

Caxton Corporation sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2017, closing a stake of 1,997 shares — an estimated $306K sold.

Caxton Corporation first reported a position in JAZZ in Q1 2017 and held it in 3 quarters. The position peaked at $309K in Q2 2017. 323 funds tracked by Wall St. Rank hold JAZZ as of Q4 2017.

  • Caxton Corporation reported no remaining Jazz Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Caxton Corporation sold 1,997 Jazz Pharmaceuticals shares in Q4 2017, an estimated $306K.
  • Caxton Corporation first reported a position in Jazz Pharmaceuticals in Q1 2017 and held it in 3 quarters.
  • Caxton Corporation's Jazz Pharmaceuticals position peaked at $309K in Q2 2017.
  • 323 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2017.

Based on Caxton Corporation's 13F filing for Q4 2017, filed 14 Feb 2018.